Diligence memo · auto-generated · as of July 2, 2026
Pharmaceutics International, Inc.
Pharmaceutics International, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Pharmaceutics International, Inc. operates in Pharmaceuticals, based in HUNT VALLEY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pharmaceutics International, Inc. has raised $206M in disclosed capital across 17 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $108M on 2016-08-31.
Most recent recorded round closed around 2024-06-03.
Valuation (modeled)modeled
Provath models Pharmaceutics International, Inc. at approximately $124M (range $54M–$174M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.06× the median modeled value of Series D+ Pharmaceuticals companies in 2022–2024 (18 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round was 2.6× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 59% of those peers.
Closest niche peers: Paragon Biosciences Emalex Capital, Inc., TrialSpark, Inc., Fog Pharmaceuticals, Inc., MAPS Public Benefit Corp, Karyopharm Therapeutics Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.